8431598

8 known cases. View patent page →

Cases: 8
Active: 1; 7 closed
Filed: 2012–2019
Top venue: D N J; 8 cases

Filing activity

Cases asserting US Patent 8431598 filed per year.

Celgene Corporation v. Natco Pharma Ltd. et al.

settled/consent judgment

Docket:: 2:12-cv-04571
Court:: D.N.J.
Filed:: 2012-07-20
Terminated:: 2016-01-04

Patents:7977357 8431598

π Celgene Corporation Δ Natco Pharma Ltd.Δ Arrow International Ltd.Δ Watson Laboratories, Inc.Δ Watson Pharmaceuticals

Celgene asserted U.S. 7,977,357 against Natco, Arrow, and Watson in a REVLIMID ANDA litigation. The case settled and a consent judgment entered Jan. 4, 2016 dismissed claims with prejudice and enjoined Natco from generic lenalidomide except under license. The May 27, 2014 Markman opinion in the Natco litigation also construed 'Form A' for the '357 and '598 patents.

Celgene Corporation v. Cipla Limited

settled/consolidated

Docket:: 2:18-cv-08964
Court:: D.N.J.
Filed:: 2018-05-08
Terminated:: 2020-12-11

Patents:7977357 8193219 8431598

π Celgene Corporation Δ Cipla Limited

Celgene sued Cipla over lenalidomide, and on Apr. 30, 2019 Cipla stipulated it would not contest infringement of the '357, '219, and '598 patents while reserving invalidity. The case was administratively terminated and consolidated into 2:19-cv-14731 on June 8, 2020, and ultimately settled Dec. 11, 2020.

Celgene Corporation v. Sun Pharmaceutical Industries et al.

settled

Court:: D.N.J.

Patents:7977357 8193219 8431598

π Celgene Corporation Δ Sun Pharmaceutical Industries Δ Sun Pharma Δ U.S. subsidiary

Celgene and Sun settled a Hatch-Waxman lenalidomide action in July 2021. The asserted patents identified in the settlement were U.S. 7,977,357, 8,193,219, and 8,431,598, with volume-limited sales after March 2022 and unlimited after Jan. 2026; the Hatch-Waxman actions were dismissed.

Celgene Corp. v. Cipla Ltd.

settled

Docket:: 2:19-cv-14731
Court:: D.N.J.
Filed:: 2019-07-03

Patents:7977357 8193219 8431598

π Celgene Corp.Δ Cipla Ltd.

Celgene's consolidated action against Cipla consolidated 2:17-cv-06163 and 2:18-cv-08964. It settled in Dec. 2020; the consolidated Cipla action carried the '357, '219, and '598 patents from 2:18-cv-08964.

Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc. et al.

active

Docket:: 2:18-cv-08519
Court:: D.N.J.
Filed:: 2018-04-27

Patents:8431598

π Celgene Corporation Δ Zydus Pharmaceuticals (USA) Inc.Δ Cadila Healthcare Limited

Celgene asserted the '357, '219, and '598 patents against Zydus/Cadila. Assigned to Judge Wigenton. DrugPatentWatch shows the case not terminated as of 2025-10-05; final disposition unconfirmed.

Celgene Corporation v. Lotus Pharmaceutical Co., Ltd. et al.

settled/consent judgment

Docket:: 2:18-cv-11518
Court:: D.N.J.
Filed:: 2018-07-10

Patents:8431598

π Celgene Corporation Δ Lotus Pharmaceutical Co., Ltd.Δ Alvogen, Inc.

Celgene sued Lotus and Alvogen over ANDA No. 210480, asserting the '357, '219, and '598 patents. Markman hearings were canceled in 2019, and the docket reflects a judgment/injunction barring marketing. The case is the only '598 case indexed in the Stanford NPE Database and ended in consent judgment/injunction.

Celgene Corporation v. Sun Pharma Global FZE

settled/consent judgment

Docket:: 2:19-cv-10099
Court:: D.N.J.
Filed:: 2019-04-16
Terminated:: 2021-06-22

Patents:8431598

π Celgene Corporation Δ Sun Pharma Global FZE

Celgene asserted the unlisted Orange Book patents '357, '219, and '598 against Sun Pharma Global FZE. The court denied Sun's motion to dismiss, holding § 271(e)(2) jurisdiction does not require Orange Book listing or Paragraph IV certification. Consent judgment entered 2021-06-22, enjoining Sun until expiration of patents including the '598.

Untitled case

unverified

Docket:: 2:19-cv-13994
Court:: D.N.J.

Patents:8431598

Docket number on Google Patents' litigation panel for US 8,431,598; parties, asserted patents, and outcome unresolved/requires direct docket verification.